- Home
- XPRO vs SYRE Comparison
XPRO vs SYRE Comparison
Compare XPRO & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPRO
- SYRE
- Stock Information
- Founded
- XPRO 1938
- SYRE 2013
- Country
- XPRO United States
- SYRE United States
- Employees
- XPRO N/A
- SYRE N/A
- Industry
- XPRO Oilfield Services/Equipment
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- XPRO Energy
- SYRE Health Care
- Exchange
- XPRO Nasdaq
- SYRE Nasdaq
- Market Cap
- XPRO 935.2M
- SYRE 841.4M
- IPO Year
- XPRO 2013
- SYRE 2016
- Fundamental
- Price
- XPRO $8.32
- SYRE $15.30
- Analyst Decision
- XPRO Buy
- SYRE Buy
- Analyst Count
- XPRO 3
- SYRE 6
- Target Price
- XPRO $12.00
- SYRE $55.00
- AVG Volume (30 Days)
- XPRO 1.1M
- SYRE 490.0K
- Earning Date
- XPRO 07-24-2025
- SYRE 05-08-2025
- Dividend Yield
- XPRO N/A
- SYRE N/A
- EPS Growth
- XPRO N/A
- SYRE N/A
- EPS
- XPRO 0.58
- SYRE N/A
- Revenue
- XPRO $1,720,185,000.00
- SYRE N/A
- Revenue This Year
- XPRO N/A
- SYRE N/A
- Revenue Next Year
- XPRO $2.76
- SYRE N/A
- P/E Ratio
- XPRO $14.30
- SYRE N/A
- Revenue Growth
- XPRO 10.48
- SYRE N/A
- 52 Week Low
- XPRO $6.70
- SYRE $10.91
- 52 Week High
- XPRO $24.50
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- XPRO 49.29
- SYRE 51.16
- Support Level
- XPRO $7.57
- SYRE $14.87
- Resistance Level
- XPRO $8.70
- SYRE $15.71
- Average True Range (ATR)
- XPRO 0.33
- SYRE 0.72
- MACD
- XPRO 0.07
- SYRE 0.10
- Stochastic Oscillator
- XPRO 46.87
- SYRE 51.57
About XPRO Expro Group Holdings N.V.
Expro Group Holdings NV offers products and services that span the well life cycle, including well construction, well flow management, well intervention and integrity, and subsea well access. It maintains operations around the world and specializes in offshore production solutions. It also provides production optimization for both onshore and offshore applications. The company has four operating segments: North and Latin America (NLA); Europe and Sub-Saharan Africa (ESSA); Middle East and North Africa (MENA), and Asia-Pacific (APAC). The majority of its revenue is derived from North and Latin America (NLA) segment.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.